Engineered CMV gB Proteins for Environmental Monitoring and Control

Publication ID: 24-11857622_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Engineered CMV gB Proteins for Environmental Monitoring and Control,” Published Technical Disclosure No. 24-11857622_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857622_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,622.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of engineered mutant cytomegalovirus glycoprotein B (gB) proteins to develop novel systems and methods for monitoring and controlling environmental threats, such as crop diseases, invasive species, water pollutants, pest populations, and wildfires.

Background and Problem Solved

The original patent disclosed engineered mutant CMV gB proteins with improved stability and binding properties. However, the patent's scope was limited to human cytomegalovirus and its applications. The present inventive concept addresses the need for innovative solutions in environmental monitoring and control, where current methods are often inadequate, expensive, or invasive.

Detailed Description of the Inventive Concept

The new claims describe systems and methods that utilize engineered mutant CMV gB proteins modified to bind specifically to various environmental targets, such as disease-causing pathogens, invasive species, pollutants, pests, or fire-related chemicals. These proteins provide a detectable signal upon binding, enabling real-time monitoring and control of environmental threats. The inventive concept encompasses a range of applications, including crop disease monitoring, invasive species tracking, water pollution detection, pest population control, and wildfire detection.

Novelty and Inventive Step

The new claims introduce a paradigm shift by applying the core technology of engineered mutant CMV gB proteins to entirely new fields, including environmental monitoring and control. This inventive step lies in the unexpected use of these proteins to address pressing environmental challenges, demonstrating a non-obvious connection between the original patent's technology and these novel applications.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different protein modifications, such as fluorescent or magnetic labels, to enhance detection capabilities. Variations may also involve the development of portable or handheld devices for in-field monitoring, or the integration of machine learning algorithms to improve predictive capabilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including agriculture, environmental consulting, water treatment, pest control, and firefighting. The market for environmental monitoring and control systems is growing rapidly, driven by increasing concerns about climate change, sustainability, and public health.

CPC Classifications

SectionClassGroup
A A61 A61K39/245
C C07 C07K14/045
C C12 C12N7/00
C C12 C12N2710/16134

Original Patent Information

Patent NumberUS 11,857,622
TitleHuman cytomegalovirus GB polypeptide
Assignee(s)Pfizer Inc.